Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.InflaRx has completed the Phase I study of IFX-1, a new first in class monoclonal antibody inhibiting complement driven inflammation.
Subscribe to our email newsletter
The trial demonstrated that IFX-1 is safe and well tolerated while displaying desirable PK and PD parameters and reached its anticipated endpoints.
IFX-1 was designed to control the inflammatory response in acute diseases, lead by the sepsis indication.
InflaRx co-founder and CEO said Niels Riedemann said they completed successful clinical Phase I trial with IFX-1 within their first financing round and in less than four years development.
"Our strategic positioning in Jena, with our strong clinical ties to the sepsis, puts us in a unique position to tackle the challenges of clinical development of IFX-1," Riedemann added.